RxDoctor Payments DataLook up a doctor →

Raghava Gollapudi, MD

Interventional Cardiology · San Diego, CANPI 1467429191

Payments from drug & device makers

$841,725in general payments, 2019–2025

Across 957 payments — averaging $879.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$529K
  • Boston Scientific$156K
  • Edwards Lifesciences$100K
  • AstraZeneca$30K
  • Shockwave Medical, Inc$7K
  • Philips North America LLC$6K
  • plus $13K from 51 others

What the payments were for

  • Consulting fees$200,38840%
  • Speaking & faculty fees$192,47539%
  • Grants$1000%
  • Travel & lodging$82,35317%
  • Food & beverage$23,3275%
  • Education$830%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$841,725 in reported general payments places this provider in the 95th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$382,935
Medicare patients
1,164
Services billed
3,342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$107,092
BrilintaTicagrelor44$42,425
EntrestoSacubitril/Valsartan21$29,263
Repatha SureclickEvolocumab20$21,601
Ezetimibe21$1,924
Atorvastatin Calcium167$1,881
ClopidogrelClopidogrel Bisulfate126$1,200
Metoprolol Succinate80$1,174
Amlodipine Besylate154$1,162
Losartan Potassium121$937
Rosuvastatin Calcium32$740
Metoprolol Tartrate77$673
Cilostazol14$623
Isosorbide Dinitrate24$495
Furosemide71$447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$56$107,09289 claims
AstraZenecaBrilinta$30,072$42,42544 claims
NovartisEntresto$259$29,26321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →